Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(11):825; doi:10.1093/jnci/96.11.825
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Gene Mutation May Predict Lung Cancer Patients’ Response to Iressa

Patients with non-small cell lung cancer (NSCLC) whose tumor cells have a mutation in the gene that produces a protein called epidermal growth factor receptor (EGFR) are more likely to respond to the drug gefitinib (Iressa) than patients without the mutation, according to two new studies.

Iressa was approved by the U.S. Food and Drug Administration 1 year ago for the treatment of lung cancer.

In clinical trials, however, Iressa caused tumor regression in only a small subset of patients. The drug was more likely to work in patients from Japan, in women, in nonsmokers, and . . . [Full Text of this Article]

Pap Smears and Mammograms Should Be Directed at Healthy Elderly Women

Highly Processed Soy May Increase Breast Cancer Growth


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?